Lymphatic vessels are essential for tissue fluid homeostasis, immune cell trafficking, and intestinal lipid absorption. The lymphatics have long been recognized to serve as conduits for distant tumor dissemination. However, recent findings suggest that the regional lymphatic vasculature also shapes the immune microenvironment of the tumor mass and potentiates immunotherapy. This review discusses the role of lymphatic vessels in tumor metastasis and tumor immunity.
Introduction
Metastasis is the primary cause of morbidity and mortality in cancer patients (Guan, 2015) . Although it was recognized centuries ago that patients with a higher tumor burden in sentinel lymph nodes have worse prognoses (Shayan et al., 2006) , the notion that the lymphatic vasculature is fundamental to tumor metastasis was appreciated only about two decades ago (Karaman and Detmar, 2014) . Pioneering murine studies demonstrated that the induction of lymphatic vascular overgrowth promotes tumor metastasis (Skobe et al., 2001; Stacker et al., 2001) . A later clinical investigation revealed that tumor lymphatic vessel amplification predisposes human melanoma to metastasis (Dadras et al., 2003) . However, a recent study demonstrated that enhancing lymphangiogenesis augments the efficacy of cancer vaccine-and checkpoint blockade-mediated immunotherapy (Fankhauser et al., 2017) , providing the first evidence that the promotion of cancer lymphangiogenesis might be harnessed to potentiate immune modulatory treat-ments. Further investigation is, therefore, urgently needed to gain a better understanding of how lymphatics may affect tumor pathology. This review summarizes the role of the lymphatic vasculature in tumor metastasis as well as tumor immunobiology.
Lymphatic vascular system
The lymphatic system is a unidirectional circulatory network that is essential for tissue fluid homeostasis, dietary fat absorption, and the regulation of immune responses . The lymphatic vascular tree begins as blind-ended capillaries comprised of a single layer of lymphatic endothelial cells (LECs) that tether to the surrounding tissue through anchoring filaments (Stacker et al., 2014) ; junctional proteins, such as vascular endothelial cadherin (VEcadherin), claudin-5, occludin, zonula occludens-1 (ZO-1), and endothelial cell-selective adhesion molecule (ESAM), form discontinuous button-like structures that interconnect capillary LECs and facilitate the uptake of interstitial fluid, macromolecules, and cells (Baluk et al., 2007; Mortimer and Rockson, 2014) . The capillaries converge into pre-collectors that further merge into collecting lymphatics, where continuous zipper-like junctions join LECs (Baluk et al., 2007) . Collecting lymphatics are invested with smooth muscle cells and contain intraluminal valves that permit unidirectional lymph flow (Mäkinen et al., 2007) . Lymphatic vascular deficiency or dysfunction causes lymphedema, a chronic disfiguring disorder that affects millions of patients globally (Tian et al., 2017; Jiang et al., 2018; Rockson et al., 2018) . Also notable is the fact that pathological lymphatic remodeling occurs in a myriad of acute or chronic disorders, such as cardiac, pulmonary, renal, and neurodegenerative diseases, and improving the lymphatic circulation in those conditions appears to be beneficial (Aspelund et al., 2016; Henri et al., 2016; Stump et al., 2017; da Mesquita et al., 2018; Lopez Gelston et al., 2018; Vieira et al., 2018) . This review focuses on lymphatics in cancer pathology.
Tumor lymphangiogenesis
Lymphangiogenesis is the process of new lymphatic vessel formation from preexisting vasculature, a phenomenon that is important for both embryonic development and adult tissue homeostasis (Tammela and Alitalo, 2010) . It is a tightly regulated process that requires the coordination of multiple inter-and intracellular signaling cascades (Zheng et al., 2014) . The vascular endothelial growth factor (VEGF)-C/Dinduced activity of VEGF receptor (VEGFR)-3 elicits the central signaling that stimulates lymphangiogenesis in both physiological and pathophysiological conditions (Jeltsch et al., 1997) . Other molecules, including fibroblast growth factor-2 (FGF2), angiopoietins, sphingosine-1-phosphate (S1P), neuropilin 2 (NRP2), bone morphogenetic protein 9 (BMP9), and Notch1, also participate in the generation of new lymphatic vasculature (Zheng et al., 2014) . Prolymphangiogenic interleukin (IL)-1β and tumor necrosis factor (TNF)-α and anti-lymphangiogenic IL-4 and IL-13 also regulate lymphangiogenesis, especially during inflammation (Baluk et al., 2009 (Baluk et al., , 2013 Shin et al., 2015; Sainz-Jaspeado and Claesson-Welsh, 2018) . Furthermore, interstitial pressure and flow rate can guide lymphangiogenesis (Boardman and Swartz, 2003) . LEC-expressed proteases, such as matrix metalloproteinase (MMP) 9 and MMP2, and integrins, such as Itga9 and α5β1, are also involved in new lymphatic vasculature formation (Vaahtomeri et al., 2017) , suggesting that lymphangiogenesis requires extracellular matrix (ECM) remodeling as well as a bidirectional LEC and ECM communication. Analogous to that of blood vascular angiogenesis, the lymphangiogenic process utilizes the Notch signaling pathway to enhance lymphatic stabilization by promoting a stalk cell phenotype of proliferating LECs (Zheng et al., 2011) . More recently, LEC metabolic processes, such as fatty acid oxidation (FAO) and glycolysis, have been shown to regulate lymphangiogenesis (Wong et al., 2017; Yu et al., 2017) , highlighting the importance of cellular metabolism in regulating lymphatic development and regeneration.
Similar to that in tumor angiogenesis, tumor lymphangiogenesis produces abnormal lymphatic vessels, which allow retrograde fluid flow and make liquid transportation inefficient (Ariffin et al., 2014) . It was hypothesized that, during tumor progression, accumulating mutations enable tumor cells to produce pro-lymphangiogenic growth factors that initiate lymphangiogenesis, a process known as the lymphangiogenic switch (Cao, 2005) . For example, the mutation of the tumor suppressor gene p53 and the activation of oncogenes Ras and Myc enhance the expression of FGF2, VEGF, and platelet-derived growth factor (PDGF), which drives initial tumor lymphangiogenesis (Ueba et al., 1994; Arbiser et al., 1997; Enholm et al., 1997; Su et al., 2001; Uramoto et al., 2004) . Tumor cells can produce S1P and prostaglandin E2 (PGE2) to promote lymphatic growth (Nandi et al., 2017; Yamada et al., 2018) . Tumors also indirectly enhance lymphatic growth by activating fibroblasts to secrete VEGF-C and hepatocyte growth factor (HGF) (Wei et al., 2017; Gao et al., 2018) , as well as by recruiting tumor-associated macrophages (TAMs) and mast cells to produce VEGF-C/D and IL-1β (Harvey and Gordon, 2012; Weichand et al., 2017; Varricchi et al., 2018) . Moreover, escalated interstitial pressure, resulting primarily from increased blood vessel leakage, provides guidance cues and promotes lymphatic expansion (Kim et al., 2016) . A more recent study showed that the chemotherapeutic agent docetaxel reprograms breast cancer cells to preferentially express pro-lymphangiogenic factors, including VEGF-C and TNF-α to promote lymphatic sprouting (Harris et al., 2018) . Cumulatively, these findings suggest that cancer cells, tumor microenvironment, and treatment interventions enhance lymphangiogenesis and abnormal lymphatic remodeling in the tumor (Fig. 1) .
Tumor-induced lymphangiogenesis also occurs in the draining lymph nodes, where new lymphatic vessel formation is observed to take place before the arrival of the metastatic tumor cells, indicating that circulating pro-lymphangiogenic factors that originate from the primary tumor mass may play a central role in this process (Hirakawa et al., 2005) . After arrival to the lymph nodes, tumor cells promote local lymphatic growth by continuously supplying VEGF-C (Kerjaschki et al., 2011) . Lymphatic vessel expansion in draining lymph nodes appears to be an important step for distant tumor metastasis (Hirakawa et al., 2007; Karaman and Detmar, 2014) .
Lymphatic routes for tumor metastasis
Decades of research has provided a comprehensive understanding of the cellular and molecular mechanisms involved in tumor metastasis through the blood vascular circulation (Lambert et al., 2017) . Tumor cell dissemination through the bloodstream involves a sequential, multiple-step invasion-metastasis cascade. During this process, tumor cells endure hydrodynamic flow and shear stress, as well as manage to escape destruction by circulating immune cells present in the blood circulation; tumor cells also develop programs that subvert the induced dormancy during transit, which allow cancer stem cells (CSCs) within the migrating cell population to maintain their ability to re-initiate tumor growth at distant new locations (Lambert et al., 2017) . Lymphatic metastasis, on the other hand, involves tumor cell transport in both lymphatic and blood vessels (Proulx and Detmar, 2013; Paduch, 2016) .
Mechanisms of immune cell trafficking in lymphatics are well-studied (Randolph et al., 2016) . Tumor cells highjack immune trafficking machinery to facilitate their own entry and transport within the lymphatic system. LEC-produced chemokines, including C-C motif chemokine ligand 21 (CCL21) and CCL19, are the most important factors that guide and recruit immune cells that express C-C motif chemokine receptor 7 (CCR7); mice lacking CCR7 expression have defective T cells and dendritic cells (DCs) homing to the lymph nodes (Förster et al., 2008) . Increased CCR7 expression occurs in several human cancers, and a higher level of CCR7 expression correlates with increased distant metastasis (Müller et al., 2001) , suggesting that tumor cell lymphatic invasion similarly employs CCR7-mediated chemotaxis. The CXCL12/CXCR4 and CX3CL1/ CX3CR1 axes have been shown to play roles in directing DC trafficking (Imai et al., 1997; Kabashima et al., 2007a Kabashima et al., , 2007b Jackson, 2014) . In tumors, chemokine receptor pairs, including CXCL12/CXCR4 and CCL1/CCR8, also play a role in promoting metastasis (Hirakawa et al., 2009; Das et al., 2013) (Fig. 2) . Although tumor masses often display lymph stasis, this may not significantly impede cancer cell lymphatic intravasation, because cellular uptake depends primarily on the chemotactic guidance gradient (Randolph et al., 2016) . As for the site of entry, the immune cells prefer to use the regions of the lymphatic capillaries with sparse basement membrane, known as portals (Pflicke and Sixt, 2009) . Tumor cells likely also enter lymphatics primarily through those locations. While the bloodstream may pose multiple obstacles to circulating tumor cells (Lambert et al., 2017) , the lymphatic vasculature might provide a protective microenvironment that promotes the survival of in-transit tumor cells; LECs might also provide a niche for cells with CSC properties (Karaman and Detmar, 2014). In summary, the lymphatic
Fig. 1 Scheme of tumor lymphangiogenesis
Tumor cells produce FGF2, PDGF, VEGF, S1P, and PGE2, which directly induce lymphangiogenesis. Tumor cells also activate fibroblasts and recruit inflammatory cells, including mast cells and macrophages, which in turn produce VEGF-C/D, HGF, and IL-1β to enhance lymphangiogenesis. Chemotherapy promotes lymphangiogenesis by reprogramming cancer cells to express VEGF-C and TNF-α. Interstitial fluid flow provides directional guidance for lymphangiogenesis. FGF2, fibroblast growth factor-2; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; S1P, sphingosine-1-phosphate; PGE2, prostaglandin E2; HGF, hepatocyte growth factor; IL, interleukin; TNF, tumor necrosis factor route likely has an advantage over the blood route for cancer cell dissemination, and the former may represent a preferable path for distant tumor dissemination (Mortimer and Rockson, 2014) .
Epithelial-mesenchymal transition (EMT) is a well-described phenomenon that occurs during blood vessel metastasis (Lambert et al., 2017) . Intriguingly, recent findings suggest that the EMT program may also play a role in lymphatic invasion (Karlsson et al., 2017) , which may sound counterintuitive, since the unique button-like structure of the lymphatic capillary does not seem to require cellular transformation for lymphatic intravasation. However, given the notion that the transitional state between the epithelial and mesenchymal phenotypes might skew malignant cells to CSCs and facilitate tumor re-growth (Lambert et al., 2017) , the EMT program in lymphatic dissemination may well be an important step.
Lymphatic vessels in tumor immunobiology
Cancer is a genetic disease initiated by oncogenic mutations. Once formed, tumors typically gain additional mutations or epigenetic modifications to sustain their growth. Genomic diversity provides an advantage for cancer cell survival, but also increases the likelihood that those malignant cells might be detected and killed by the host immune system (Jiang and Shapiro, 2014; Schumacher and Schreiber, 2015; Chen and Mellman, 2017) . Although the lymphatic vessels are known to promote immunity (Hos and Cursiefen, 2014) , a positive correlation between lymphatic density and immune response in human cancer was not revealed until recently (Lund et al., 2016) . In transgenic mice (K14-VEGFR3-Ig) that lack dermal lymphatic vessels, syngeneic B16F10 melanoma displayed significantly lower infiltration of immune cells, including B cells, T cells, and proinflammatory myeloid cells, as well as diminished expression of a panel of inflammatory mediators (Lund et al., 2016) . This finding suggests that induction of tumor immunity requires functional lymphatic vasculature. Consistent with this observations, lymphatic vessels were shown to facilitate tumor antigen-loaded DC trafficking and T cell priming (Roberts et al., 2016) ; in B16 melanoma-bearing mice with dysfunctional lymphatics, the draining lymph nodes have decreased levels of tumor antigens and lower numbers of cytotoxic CD8 + T cells, and those cells possess lower anti-tumor cytotoxicity (Kimura et al., 2015) . In agreement with these preclinical findings, a clinical study showed that, in colorectal cancers (CRCs), distant metastasis occurs more frequently when tumors have a lower immune cytotoxicity profile (Mlecnik et al., 2016) . The same study showed that tumors with lower peritumoral lymphatic vascular density tend to be more metastatic, indicating a positive correlation between lymphatic vascular density and tumor immune cytotoxicity profile. These investigations collectively demonstrate that the lymphatics participate in promoting anti-tumor immune responses and in shaping the tumor immune microenvironment.
Development of anti-tumor immunity takes place primarily in tumor-draining lymph nodes (TDLNs) (Chandrasekaran and King, 2014; Yeo and Angeli, 2017) . Newly formed tumor lymphatic vasculature provides a conduit for the transportation of Tumor lymphatic vasculature not only primes the antitumor immunity but also induces suppressive immunity by producing molecules, including TGF-β, IDO, and NO. LEC expression of MHCs and PD-L1 confers them the ability to induce T cell tolerance by acting as tolerogenic APCs directly. Lymphatic vasculature provides a conduit for tumor metastasis; LEC expression of CCL21, CCL19, CXCL12, and CCL1 facilitates tumor cell lymphatic intravasation. Lymphatic-induced suppressive microenvironment not only negatively impacts anti-tumor immunity but also promotes metastasis. Promoting tumor lymphangiogenesis may augment the efficacy of immunotherapy. TGF, transforming growth factor; IDO, indoleamine-2,3-dioxygenase; NO, nitric oxide; LEC, lymphatic endothelial cell; MHC, major histocompatibility complex; PD-L1, programmed death-ligand 1; APC, antigen-presenting cell; CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand tumor antigens to the draining lymph nodes to facilitate T cell priming (Thomas et al., 2016) . Through the lymph flow, tumor-derived antigens can be directly delivered to DCs or B cells residing in the TDLNs (Roozendaal et al., 2009; Thomas et al., 2016) . DCs patrolling peripheral tissues also take up tumor antigens, enter lymphatic vessels, and invade TDLNs (Thomas et al., 2016) . Antigen-loaded DCs then prime naive T cells and induce antigen-specific antitumor immunity. It is worth noting that the local immune signaling microenvironment during antigen presentation may influence the quality of the adaptive immunity, i.e., immune activation or tolerance (Nishikawa and Sakaguchi, 2014; Thomas et al., 2016) . The lymphatic vasculature within the tumor may also impact TDLN architecture and function by influencing the delivery of inflammatory modulators, exosomes, and microparticles from the tumor microenvironment (Robbins and Morelli, 2014; Rohner et al., 2015) . In line with the role of TDLNs in promoting anti-tumor immunity, nanoparticle-mediated adjuvant therapy targeting TDLNs enhanced tumor immunity characterized by increased cytotoxic T cells and decreased Treg cells within TDLNs (Thomas et al., 2014) . Therapeutic vaccination targeting TDLNs also enhanced anti-tumor immunity (Jeanbart et al., 2014) . Elevation of CCL3 expression in the tumor microenvironment resulted in reduced tumor growth, presumably by enhancing DC homing to TDLNs and strengthening anti-tumor immunity (Allen et al., 2017) . Furthermore, effective checkpoint inhibition therapy requires functional TDLNs (Fransen et al., 2018) . These studies indicated that TDLNs are not only vital for the development of anti-tumor immunity but also critical for the acquisition of optimal immunotherapeutic efficacy.
In addition to their function in immune activation, lymph nodes are important sites for the maintenance of self-tolerance (Förster et al., 2008) . The lymphatic vasculature also controls self-tolerance by providing a conduit for lymph-borne antigen transportation and regulating the structural organization of the draining lymph nodes (Thomas et al., 2016 ). The lymphatic system not only elicits anti-tumor immune responses but also promotes tolerance against tumors (Chen and Mellman, 2017) . Recent studies provided evidence that LECs participate in the induction of peripheral tolerance through diverse mechanisms, under both physiological and pathological conditions (Card et al., 2014; Randolph et al., 2016; Cui et al., 2017) . Because LECs express peripheral tissue antigens and major histocompatibility complex (MHC) molecules, they can directly recognize and suppress T cell activation when the expression levels of inhibitory receptor programmed death-ligand 1 (PD-L1) are high and those of co-stimulatory molecules are low (Lee et al., 2007; Nichols et al., 2007; Malhotra et al., 2012; Tewalt et al., 2012) . LEC expression of PD-L1 was later shown to be strongly induced by interferon γ (IFNγ) (Dieterich et al., 2017) , and lymphaticspecific deletion of IFNγ receptor (IFNγR) dampened LEC-mediated immune suppression and enhanced tumor immunity (Lane et al., 2018) . Because IFNγ is a cytokine that marks immune activation and is produced predominantly by immune effector cells (Schoenborn and Wilson, 2007) , PD-L1 induction by IFNγ may represent a natural feedback mechanism employed by the immune system to achieve equilibrium. LECs also produce immunosuppressive mediators, including transforming growth factor-β (TGF-β), nitric oxide (NO), and indoleamine-2,3-dioxygenase (IDO), to induce tolerant DCs and suppress T cell function (Lukacs-Kornek et al., 2011; Nörder et al., 2012; Christiansen et al., 2016) . Accordingly, the lymphatics not only induce an active immune response characterized by CD8 + T cell infiltration but also foster a suppressive microenvironment by increasing LEC expression of IDO, inducible nitric oxide synthase (iNOS), and arginase-1 in human tumors (Bordry et al., 2018) . Lastly, the lymphatic system can also induce tolerance by directly presenting tumor-derived antigens to activated CD8 + T cells to suppress their activity (Lund et al., 2012) . Collectively, these recent findings indicated that tumor lymphatics control both immune activation and tolerance (Fig. 2) .
Concluding remarks
The lymphatic circulatory system is relatively understudied in cancer compared to the blood vascular system (Folkman, 1971) . Recent advances indicate that the tumor-associated lymphatic vasculature is not just a passive conduit for metastasis; it also fulfills vital functions in shaping the immune and inflammatory responses of the tumor microenvironment. Given the current success in harnessing the immune system to improve the outcome of cancer patients (Chen and Mellman, 2017) , it is conceivable that modulating the lymphatic vascular system and TDLNs in conjunction with immunotherapeutic strategies will promote treatment efficacy while ideally reducing unwanted side effects (Fig. 2) .
